Ongoing Clinical Trials Assessing Dapagliflozin in Patients with Heart... | Download Scientific Diagram
Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists - ScienceDirect
Visual Abstract | DAPA-HF - American College of Cardiology
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver? | SpringerLink
JFP - Diabetes Volume 68, No. 01
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial - ScienceDirect
ABCD - nationwide dapagliflozin audit
DECLARE-TIMI 58 – TIMI STUDY GROUP
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM
SGLT2 inhibitor reduces CV death and worsening HF events in HFrEF patients - PACE-CME
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function - Kidney International
Efficacy results of randomized clinical trials with dapagliflozin... | Download Table
SGLT2 inhibitors – looking beyond glucose-lowering in diabetes | Cochrane UK
Forxiga (dapagliflozin) for Treatment of Type 2 Diabetes - Clinical Trials Arena
Safety of dapagliflozin in clinical trials for type 2 diabetes mellitus - Virtual Meeting | EASD
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy - Kidney International
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial - The Lancet Diabetes & Endocrinology
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial | Nature Medicine
New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin | tctmd.com
Dapagliflozin in Heart Failure | NEJM Resident 360 <meta property="twitter:image" content="https://resident360files.nejm.org/image/upload/c_fit,f_auto,h_120,w_120/v1538599218/u8buf4o8mgdxgmfcczjk.png" /> <meta property="og:image" content="https ...
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions - ScienceDirect
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials - The Lancet Diabetes & Endocrinology
Figure 1 from Efficacy and safety of Dapagliflozin vs. Canagliflozin in addition to metformin for treatment of type 2 diabetes, a randomized, double-blind, non-inferiority clinical trial | Semantic Scholar
